ASH 2007
American Society of Hematology Annual Meeting
Interviews and expert commentary from ASH 2007 — study authors and key opinion leaders discuss the findings and their clinical implications.
Audio Journal of Oncology in Advance – March 15th, 2008
Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007
Audio Journal of Oncology in Advance – March 1st, 2008
Volume 16 Number 5 (March 1st, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando) A
Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
Anton Hagenbeek ANTON HAGENBEEK, University Medical Centre Utrecht For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free surv
Live Report from ASH:<br />Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?
Christian Geisler CHRISTIAN GEISLER, Rigshospitalet, Copenhagen Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek T
Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
Susan O’Brien SUSAN O’BRIEN, MD Anderson Cancer Center, Houston For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamid
Live Report from ASH:<br />Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
Richard Stone RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute New data shows that dasatinib is giving durable responses in patients with chronic phase
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
Pierre Fenaux PIERRE FENAUX, Paris 13 University Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with
Live Report from ASH:<br />Interleukin-2 For Acute Myeloid Leukemia In First Remission?
Jonathan Kolitz JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY GEORGE CANELLOS, Dana-Farber Cancer Institute For patients with acute myeloid leukemia in first remission, new data suggests tha
New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chroni
No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia
Zakari Aliyu REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta ZAKARI ALIYU, Howard University, Washington DC Nigeria has the highest incidence of sickle cell anemi
Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h